Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of MK-7240 in moderate to severe active ulcerative colitis
CTR20241356Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tulisokibart in autoimmune colitis, sponsored by Merck & Co.. Started Jul 2024; status: active.
02
Drugs
tulisokibart
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20241356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241356.